Ubiquitin carboxyl-terminal hydrolase L1, a novel deubiquitinating enzyme in the vasculature, attenuates NF-κB activation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 10, 2007, Pages 2184-2190

  Takami, Yoichi ^a   Nakagami, Hironori ^a   Morishita, Ryuichi ^a   Katsuya, Tomohiro ^a   Cui, Tai Xing ^b   Ichikawa, Tomonaga ^b   Saito, Yukihiro ^a   Hayashi, Hiroki ^a   Kikuchi, Yasushi ^a   Nishikawa, Tomoyuki ^a   Baba, Yoshichika ^a   Yasuda, Osamu ^a   Rakugi, Hiromi ^a   Ogihara, Toshio ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Atherosclerosis; Deubiquitinating enzyme; NF B; UCHL1

Indexed keywords

ACETYLSALICYLIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLASMID VECTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; MESSENGER RNA; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NITRIC OXIDE; NOS3 PROTEIN, RAT; UBIQUITIN; UCH L1 PROTEIN, RAT; UCH-L1 PROTEIN, RAT; UCHL1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BRAIN TISSUE; CARDIOVASCULAR GENE THERAPY; CAROTID ARTERY; CAROTID ARTERY INJURY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXPRESSION VECTOR; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTIMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; TISSUE REPAIR; UBIQUITINATION; VASCULAR SMOOTH MUSCLE; VASCULARIZATION; ANIMAL; BALLOON DILATATION; CAROTID ARTERY OBSTRUCTION; CELL CULTURE; DISEASE MODEL; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; PROTEIN PROCESSING; RNA INTERFERENCE; TIME; UPREGULATION;

ANIMALS; BALLOON DILATATION; CAROTID ARTERY INJURIES; CAROTID STENOSIS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; I-KAPPA B PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN; UBIQUITIN THIOLESTERASE; UP-REGULATION;

EID: 35148859639     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.142505     Document Type: Article

References (33)

1. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science. 1996;272:689-693.
2. Lenardo MJ, Baltimore D. NF-B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989;58:227-229.
3. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol. 2005;7:758-765.
4. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425-479.
5. D'Andrea A, Pellman D. Deubiquitinating enzymes: A new class of biological regulators. Crit Rev Biochem Mol Biol. 1998;33:337-352.
6. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM, Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation. 2002;105:483-489.
7. Nishikawa T, Nakagami H, Matsuki A, Maeda A, Yo CY, Harada T, Morishita R, Tamai K, Kaneda Y. Development of high-throughput functional screening of therapeutic genes, using a hemagglutinating virus of Japan envelope vector. Hum Gene Ther. 2006;17:470-475.
8. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-specific protein pGp 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 1989;246:670-673.
9. Nakagami H, Morishita R, Yamamoto K, Taniyama Y, Aoki M, Matsumoto K, Nakamura T, Kaneda Y, Horiuchi M, Ogihara T. Mitogenic and antiapoptotic actions of hepatocyte growth factor through ERK, STAT3, and AKT in endothelial cells. Hypertension. 2001;37:581-586.
10. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther. 2002;6:219-226.
11. Yoshisue H, Suzuki K, Kawabata A, Ohya T, Zhao H, Sakurada K, Taba Y, Sasaguri T, Sakai N, Yamashita S, Matsuzawa Y, Nojima H. Large scale isolation of non-uniform shear stress-responsive genes from cultured human endothelial cells through the preparation of a subtracted cDNA library. Atherosclerosis. 2002;162:323-334.
12. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193-199.
13. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation. 2002;106:57-62.
14. Nakagami H, Morishita R, Yamamoto K, Yoshimura SI, Taniyama Y, Aoki M, Matsubara H, Kim S, Kaneda Y, Ogihara T. Phosphorylation of p38 mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to cell death induced by high D-glucose in human endothelial cells. Diabetes. 2001;50:1472-1481.
15. Cui TX, Nakagami H, Nahmias C, Shiuchi T, Takeda-Matsubara Y, Li JM, Wu L, Iwai M, Horiuchi M. Angiotensin ii subtype 2 receptor activation inhibits insulin-induced phosphoinositide 3-kinase and Akt and induces apoptosis in PC12w cells. Mol Endocrinol. 2002;16:2113-2123.
16. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8478.
17. Matsushita H, Morishita R, Aoki M, Tomita N, Taniyama Y, Nakagami H, Shimozato T, Higaki J, Kaneda Y, Ogihara T. Transfection of antisense p53 tumor suppressor gene oligodeoxynucleotides into rat carotid artery results in abnormal growth of vascular smooth muscle cells. Circulation. 2000;101:1447-1452.
18. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 1989;243:375-378.
19. Matsushita H, Morishita R, Nata T, Aoki M, Nakagami H, Taniyama Y, Yamamoto K, Higaki J, Yasufumi K, Ogihara T. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-κB)-mediated bcl-2 suppression: In vivo evidence of the importance of NF-κB in endothelial cell regulation. Circ Res. 2000;86:974-981.
20. Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, Ogihara T. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Ther. 2001;8:1635-1642.
21. Anderson HD, Rahmutula D, Gardner DG. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem. 2004;9:963-969.
22. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR. Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem. 2006;281:29228-29235.
23. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
24. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395:451-452.
25. Maraganore DM, de Andrade M, Lesnick TG, Farrer MJ, Bower JH, Hardy JA, Rocca WA. Complex interactions in Parkinson's disease: A two-phased approach. Mov Disord. 2003;18:631-636.
26. Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, Toda T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol. 2002;51:133-136.
27. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron. 2003;40:427-446.
28. Meiners S, Hocher B, Weller A, Laule M, Stangl V, Guenther C, Godes M, Mrozikiewicz A, Baumann G, Stangl K. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension. 2004;44:471-477.
29. Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Li L. Oxidative modifications and down-regulation of ubiquitin carboxylterminal hydrolase l1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem. 2004;279:13256-13264.
30. Campbell LK, Thomas JR, Lamps LW, Smoller BR, Folpe AL. Protein gene product 9.5 (pGp 9.5) is not a specific marker of neural and nerve sheath tumors: An immunohistochemical study of 95 mesenchymal neoplasms. Mod Pathol. 2003;16:963-969.
31. Caballero OL, Resto V, Patturajan M, Meerzaman D, Guo MZ, Engles J, Yochem R, Ratovitski E, Sidransky D, Jen J. Interaction and colocalization of pGp9.5 with JAB1 and p27(Kip1). Oncogene. 2002;21:3003-3010.
32. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, Yeh LA, Cuny GD, Stein RL, Lansbury PT Jr. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol. 2003;10:837-846.
33. Wojcik C, Bury M, Stoklosa T, Giermasz A, Feleszko W, Mlynarczuk I, Pleban E, Basak G, Omura S, Jakobisiak M. Lovastatin and simvastatin are modulators of the proteasome, Int J Biochem Cell Biol. 2000;32:957-965.